The mycoplasma testing market is estimated to register a healthy CAGR over the forecast period. Factors, such as high spending in R&D activities by biopharmaceutical companies, increased government initiatives and funding in research activities, technological advancements, increasing demand for fast, accurate, and affordable testing, and the increasing cell culture contamination, are further driving the market for mycoplasma testing. However, there are certain stringent government regulations across several developed and emerging countries and a high degree of consolidation for new entrants, which are among the major hindrances in the growth of the mycoplasma testing market.

Key Market Trends

Polymerase Chain Reaction (PCR) Holds Significant Market Share

Polymerase Chain Reaction (PCR) is a technique that is used to amplify target DNA and generate thousands to millions of copies of a particular DNA segment. PCR techniques are used in clinical and research laboratories for a broad variety of applications, which include clinical diagnosis, criminal forensics, and biomedical research. The major factors attributed to the growth of the polymerase chain reaction segment include the increasing application in clinical diagnostics, rising demand for personalized and precision medicine, and technological advancements and applications in drug development.

For instance, in July 2018, ATCC, the premier global biological materials resource and standards organization and the leading supplier of authenticated cells and advanced cell models, launched its new PCR-based service to detect mycoplasma contamination in cell cultures. ATCC has long recognized the growing challenges among the scientific community for adventitious agent contamination included in cell-based research. Hence, the company introduced this product line to support the authentication of cell lines used in basic and translational research, and it complements the STR profiling service.

North America to Dominate the Market

North America currently dominates the mycoplasma testing market, and it is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, due to its well-established healthcare industry and the rising prevalence of chronic diseases in the region. Other factors driving the growth of this region are the presence of global biotech companies and pharmaceutical players and higher investment in R&D activities in the region. The United States holds the majority of the market share in North America. This is due to the rising healthcare expenditure, along with the rapid adoption of point-of-care testing.

Competitive Landscape

Companies are focusing on various growth strategies, such as new product launches, collaborations, acquisitions, and partnerships, to enhance their market presence. The major players include Abbott, Agilent Technologies, Charles River Laboratories International Inc., Eurofins Scientific, F. Hoffmann-La Roche Ltd, Lonza Group, Merck KGaA, PromoCell GmbH, Sartorius AG, and Thermo Fisher Scientific Inc., among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support